Asset Details
Do you wish to reserve the book?
Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study
Do you wish to request the book?
Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study
2025
Overview
Predictive value of metabolic syndrome for prostate cancer risk is not clear. We aimed to assess the association between metabolic syndrome and its components with prostate cancer incidence. The primary outcome was prostate cancer incidence, i.e., incidence rate ratios and adjusted cumulative incidence curves derived from flexible parametric survival models. Adjusted cumulative incidence curves were derived using a flexible survival parametrical modeling framework. We analysed UK Biobank data including 242,349 adult males, recruited during 2006–2010 and followed up until 2021, during which 6,467 (2.7%) participants were diagnosed with prostate cancer. Our findings indicate that metabolic syndrome, as a whole, was not associated with prostate cancer risk (incidence rate ratios, 1.07; 95% confidence interval, 0.94–1.22). However, specific components such as hypertension and obesity increased the risk (incidence rate ratios, 1.22; 95% confidence interval, 1.03–1.44 and incidence rate ratios, 1.24; 95% confidence interval, 1.05–1.46, respectively). Other components, such as prediabetes/diabetes and low cholesterol, were associated with a reduced risk (incidence rate ratios, 0.80; 95% confidence interval, 0.67–0.94 and incidence rate ratios, 0.82; 95% confidence interval, 0.69–0.97, respectively), while hyperlipidaemia showed no significant effect (incidence rate ratios, 1.07; 95% confidence interval, 0.93–1.24). Further research is needed to understand the underlying mechanisms behind these relationships. Prostate cancer prevention strategies might benefit from targeting modifiable risk factors, particularly hypertension and obesity.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/308
/ 692/499
/ 692/699
/ Aged
/ Biobanks
/ Cancer
/ Diabetes Mellitus - epidemiology
/ Diabetes Mellitus - metabolism
/ Diet
/ Exercise
/ Humanities and Social Sciences
/ Humans
/ Male
/ Metabolic Syndrome - epidemiology
/ Metabolic Syndrome - metabolism
/ Obesity
/ Prediabetic State - epidemiology
/ Prediabetic State - metabolism
/ Prostatic Neoplasms - epidemiology
/ Prostatic Neoplasms - metabolism
/ Prostatic Neoplasms - pathology
/ Prostatic Neoplasms - prevention & control
/ Science
/ Survival
